The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator’s choice in HER2-low breast cancer.
 
Shanu Modi
Speakers' Bureau - Genentech
Research Funding - Daiichi Sankyo; Novartis; Roche/Genentech; Seagen; Synta
 
Shoichiro Ohtani
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Pfizer
 
Caleb C. Lee
Employment - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Kongming Wang
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Kapil Saxena
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Bayer
 
David A. Cameron
Consulting or Advisory Role - Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Samsung Bioepis (Inst); Seagen (Inst); Synthon (Inst); Synthon (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Novartis